Compare PAYC & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAYC | PODD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 10.3B |
| IPO Year | 2014 | 2007 |
| Metric | PAYC | PODD |
|---|---|---|
| Price | $140.31 | $143.12 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | $168.79 | ★ $341.48 |
| AVG Volume (30 Days) | 893.6K | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.04 | 1.30 |
| Revenue | $433,047,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $8.79 | $24.55 |
| Revenue Next Year | $7.48 | $19.18 |
| P/E Ratio | ★ $44.96 | $109.80 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $104.90 | $140.63 |
| 52 Week High | $267.76 | $354.88 |
| Indicator | PAYC | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 29.89 |
| Support Level | $109.44 | N/A |
| Resistance Level | $145.15 | $205.95 |
| Average True Range (ATR) | 5.52 | 5.92 |
| MACD | -0.19 | 0.83 |
| Stochastic Oscillator | 69.10 | 14.12 |
Founded in 1998, Paycom is a human capital management software-as-a-service provider addressing customer requirements surrounding payroll, talent acquisition, talent management, HR management, as well as time and labor. The company primarily services midsize businesses within the United States, targeting businesses with 50-10,000 employees. The company primarily generates revenue through the sale of subscriptions providing access to its HCM platform. To a lesser extent, the company also generates revenue from implementation services provided to customers as well as interest income generated from customer funds. As of fiscal 2024, the company serviced slightly over 37,500 customers and stored data on over 7 million employees.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.